28 results
8-K
EX-99.1
MTNB
Matinas Biopharma Holdings Inc
11 Aug 22
Matinas BioPharma Reports Second Quarter 2022 Financial Results and Highlights Recent Progress
6:25am
an in vivo study of oral LNC-remdesivir in mice infected with SARS-CoV-2 demonstrated significant improvement in multiple histologic markers of lung injury
424B5
3wk35 yaqj27o12sea
18 Mar 19
Prospectus supplement for primary offering
5:15pm
8-K
EX-99.4
boal7ruvnsk7gqlt
15 Mar 19
Matinas BioPharma Announces Proposed Public Offering of Common Stock
5:15pm
424B5
wj5p3
14 Mar 19
Prospectus supplement for primary offering
12:00am
8-K
EX-10.1
fpip6l
25 Feb 19
Prominent Cardiovascular Expert, James J. Ferguson, M.D., FACC, FAHA Joins Matinas BioPharma as Chief Medical Officer
8:15am
8-K
EX-10.1
hgosw qtvwzud5usa64c
3 Jan 19
Matinas BioPharma Appoints Keith A. Kucinski, CPA, MBA as Chief Financial Officer
8:05am
8-K
EX-10.1
sz12zv3r9rfo5i ys3
15 Oct 18
Departure of Directors or Certain Officers
8:00am